+

WO2008146116A2 - Composition cosmétique à effet liftant pour soutenir les tissus cutanés relâchés - Google Patents

Composition cosmétique à effet liftant pour soutenir les tissus cutanés relâchés Download PDF

Info

Publication number
WO2008146116A2
WO2008146116A2 PCT/IB2008/001237 IB2008001237W WO2008146116A2 WO 2008146116 A2 WO2008146116 A2 WO 2008146116A2 IB 2008001237 W IB2008001237 W IB 2008001237W WO 2008146116 A2 WO2008146116 A2 WO 2008146116A2
Authority
WO
WIPO (PCT)
Prior art keywords
lysine
skin
composition according
extract
cosmetic composition
Prior art date
Application number
PCT/IB2008/001237
Other languages
English (en)
Other versions
WO2008146116A3 (fr
Inventor
Daniela Montanari
Manuela Guglielmo
Original Assignee
Labo Cosprophar Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labo Cosprophar Ag filed Critical Labo Cosprophar Ag
Priority to EP08750974A priority Critical patent/EP2148651A2/fr
Publication of WO2008146116A2 publication Critical patent/WO2008146116A2/fr
Publication of WO2008146116A3 publication Critical patent/WO2008146116A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a cosmetic composition with a lifting effect for sustaining relaxed skin tissues.
  • the present invention derives from the field of products having a cosmetic action for external use.
  • the present invention relates to a cosmetic composition for topical application, having the property of stimulating the dermis in order to sustain skin tissues undergoing structural sagging caused by natural aging and relifting parts of the face and body.
  • the skin aging process is marked by very distinct signs: the appearance of wrinkles, a variation in the skin pigmentation, loss of elasticity and compactness, relaxing of the tissues .
  • the collagen present in the dermis mainly contains type I collagen (85-90%) and in a lower quantity, type III collagen (10-15%) .
  • the dermal fibroblasts synthesize the single polypeptide chains of type I and III collagen in the form of precursors, called procollagen.
  • procollagen As type I and III procollagens are precursors of the mature collagen, their levels generally reflect the biosynthesis levels of collagen.
  • Elastic fibres consist of microfibrils of elastin and fibrillin, organized in a highly orderly arrangement. As can be deduced from the name, the main characteristic of these fibres is the high elasticity. Elastic fibres are initially isolated, they branch and anastomize form- ing a lattice. They can be easily extended, returning to their original length when the traction ceases, but they are much less resistant than collagen fibres.
  • Elastin is only present in the skin in a quantity equal to 0.6% of the dry weight, whereas the quantity of collagen reaches 72% of the dry weight of the skin.
  • the aging of the epidermis is a phenomenon which is strictly related to the aging of the dermis .
  • the epidermal cells of the basal layer reach the surface of the skin through a natu- ral progression and during this process they pass from a mature and functional stage to a stage of lifeless keratinized cells.
  • the epidermis undergoes a general thinning and loss in elasticity due to a reduction in the cell proliferation capacity.
  • the dermal-epidermal junctions become flattened, acquiring an atrophic appearance due to the shrinkage of both the dermal papillae and of the microprojections of the basal cells towards the dermis.
  • the dermis also undergoes changes which involve both a reduction in the number of fibroblasts and the content and quality of fibres which regulate the tone and elasticity of the skin.
  • the elastic and collagen fibres slacken, the quantity of hyaluronic acid decreases .
  • the visible consequences of these regressive processes are, in addition to the appearance of face wrinkles, skin withering, sagging of the skin, loss in elasticity, formation of a double chin.
  • a reduction in the collagen is typical of chronologically aged skin.
  • MMPs matrix metalloproteinases
  • elastin is continuously pro- prised throughout one's life up to an age of 50 to 93 years when the fibres have a slackened appearance rather than compact and firm.
  • the elastin constantly degrades, its structure in particular can be influenced by the action of the sun and can have anomalies mainly from 70 years-old onwards. From 30 years-old onwards, the elastin begins to degrade more rapidly with the result that by 70 years-old, most of the elastin has already degraded.
  • Domyati E.M. et al involved 86 volunteers aged between 6 and 84 years-old (from the 1 st to the 9 th decade) .
  • the intensity of the colouring of the elastin in sun-protected skin was analyzed and it was observed that this intensity significantly decreases from 49.2% in the 1 st decade to 30.4% in the 9 th decade. It was observed that with the passing of age, the site and ori- entation of the elastin undergoes alterations which could have marked functional consequences.
  • the elastin fibres become individually twisted, closely entangled with the collagen, causing a reduced conformity of the dermis.
  • dermal-epidermal junction a layer situated between the epidermis and dermis.
  • This is a structure of a glycoprotein nature which has the basic function of establishing adherence between the epidermis and dermis, regulating their exchanges and also acting as a support for the overlying epidermis.
  • the dermal- epidermal junction acts as a physical and elastic support for the epidermis; during the aging process it progressively becomes thinner and this causes skin sagging.
  • this junction consists of a lam- ina, called basal lamina which adheres to the membrane of the germinative cells of the epidermis and consists of a non-collagen glycoprotein, called "laminin” .
  • laminin a non-collagen glycoprotein
  • This is a molecule made up of 4 subunits arranged in the form of a cross . It is known that skin relaxation begins at around 30 years of age. At 40 years of age the line which marks the face oval softens and becomes undulated following the descent of the cheeks. As a result of a reduction in the thickness, elasticity and tonicity of the skin, the cheeks progressively become flabby, bags are formed under the eyes; the heaviness of the eyelids increases and the skin falls with vertical folds. The features of the face become undefined.
  • One of the general objectives of the present invention consists in providing a cosmetic composition and method capable of creating an effective dermal-support of parts of the face and body.
  • a further objective of the invention consists in providing a cosmetic composition capable of creating a lifting effect on the skin subject to skin aging marks and relifting parts of the face and body subject to structural sagging.
  • the objectives according to the present invention are achieved by providing a composition for cosmetic use as specified in claim 1. Further characteristics of the invention are indicated by the subsequent claims.
  • the present invention derives from the observation that by combining a selected polypeptide component of a marine origin capable of increasing the thickness of the dermis with at least one of two peptide components which stimulate the production of collagen and elastin, a synergic supporting action is obtained on parts of the face and body which have undergone skin sagging following a natural aging process. This lifting action is particularly evident on the face but also on the body and in cases of precocious skin aging caused by cellular damage after prolonged photo-exposure. These three active prin- ciples therefore operate on the dermis for a specific finality and with a synergic action, producing an increase in the tonicity and reducing the sagging of the tissues. The result is a cosmetic intervention of the lifting type which helps the skin of the face and body to be more tonic and sustained.
  • a cosmetic composition is therefore formulated, based on active principles which, by acting on different levels of the skin structures, produce a synergic dermal-supporting action of the skin creating a particularly appreciable effect from an aesthetic point of view.
  • the component capable of stimulating the dermis for causing an increase in its thickness is marine Aosa alga from which polypeptides are extracted whose composition is very similar to elastin.
  • Aosa alga is a green alga
  • the Applicant has observed that the use of this alga, in toto or preferably as an extract, causes a cell regeneration action on the fibroblasts of the dermis and an increase in the use of cell energy.
  • the extract which can be used within the scope of the invention is typically a concentrate of active components, mainly of a polypeptide nature, having an anti-elastase activity, i.e. inhibition of the enzymatic activity. This action is caused as a result of the change they induce in the con- formation of the enzyme, thus protecting the elasticity of the supporting fibres .
  • Aosa alga only consists of two layers of cells where the plastid forms the energy centre of the alga and is particularly rich in the amino acids proline, glycine and lysine. This alga is one of the most productive in terms of biomass due to its high energy system (cell respiration) .
  • the extract from green Aosa alga has a direct effect on the mitochondria, without acting directly on the res- piratory chain, but increasing the ATPase and cell ATP. This fact is particularly significant for creating the lifting effect as cell exchanges decrease with age and stress, so much so that the cell produces less energy and its metabolism is lowered. The skin loses its vitality and vigour, wrinkles appear and under these conditions it is necessary to increase ATP production in the cells .
  • An evaluation of the cell regeneration was effected by incubating human fibroblasts with different concentrations of the active principle.
  • the cell increase is determined by evaluating the DNA neo- synthesis with the use of 3H-thymidine traced.
  • the incorporation of 3H-thymidine traced in the DNA of human fibroblasts was such that at a concentration of 0.4% of Aosa alga extract there is a cell increase of 74% with respect to the reference.
  • the Aosa alga is subjected to the following processing phases: - washing
  • One of the two peptide components used in the composition of the invention is typically represented by one or more polypeptides containing the sequence Arginine- Glycine-Aspartic acid, typically obtained by the hydroly- sis of vegetable proteins. This sequence of amino acids ⁇
  • a test in vitro was carried out in which the formation of elastin is determined from reconstituted human skin by means of the Western-Blot method. After 15 days of incubation with 1 mg/ml of a mixture of peptides containing the sequence Arginine-Glycine-Aspartic acid, an average increase of 8% in the formation of elastin is observed.
  • the second peptide component which can be advantageously used in the formulation of the composition of the invention and which represents the third active principle forming the nucleus of molecules suitable for opposing the sagging of tissues, is a tripeptide a third of which consists of the amino acid Valine and two-thirds of the amino acid Lysine and preferably having a sequence Lys- VaI-Lys, typically produced synthetically.
  • the tripeptide is subjected to purification and evaporation in order to increase its degree of purity.
  • the tripeptide preferably used within the scope of the invention simulates the production mechanism of collagen via TGF- ⁇ (Tissue Growth Factor) of the human body.
  • TGF- ⁇ tissue Growth Factor
  • This type of activity is important within the scope of the invention.
  • ECM extracellular cutaneous matrix
  • Collagen represents the main component of the ECM of the dermal connective tissue.
  • TGF- ⁇ is in itself a key element in the synthesis of collagen as it is a molecule which remains biologically inactive until the multifunctional protein Throm- bospondin I (TSP) with the sequence Arg-Phe-Lys binds itself to TGF- ⁇ , activating it.
  • TGF- ⁇ Throm- bospondin I
  • the synthesis of collagen induced by the active principle was evaluated by determining the influence of the tripeptide on the synthesis of type I collagen in human dermal fibroblasts.
  • human prepuce fibroblasts were cultivated with different concentrations of the substance to be tested and incubated for 3 days.
  • the quantity of type I collagen is determined by means of the Elisa quantitative seed method which envisages the use of a specific antibody for type I collagen.
  • the three components of the preferred embodiment of the composition of the invention therefore act on the dermis with three different actions : the hydrolytic ex- tract of alga Ulva lactuca stimulates the proliferation of fibroblasts, the polypeptides based on arginine- glycine-aspartic acid stimulate the production of elastin and the tripeptide stimulates the synthesis of type I collagen.
  • the stimulation for the proliferation of fibroblasts induces an increase in the thickness of the dermis, whereas the two peptides stimulate the formation of collagen and elastin to restore the network of fibres responsible for tone and elasticity and to give greater support to the dermis .
  • the three main active principles consequently act on the dermis with a specific finality and synergic action: thanks to this nucleus of active principles, the dermis which is thicker as a result of the greater cell presence and the fibre network reconstituted to form the supporting mattress for the overlying epidermis, produce an increase in the tonicity and a reduction in the sagging of the tissues.
  • the result is a cosmetic intervention of the lifting type which helps the tissues to be more sustained with the final aim of cosmetically relifting parts of the face and body.
  • the three active principles can be enclosed or carried in a transporter or vehicle comprising liposomes which gradu- ally release them into the site of action.
  • the use of liposomes has the aim of facilitating the penetration of the active principles in the deeper layers of the dermis.
  • the liposomes used are preferably of the multilamellar type and conveniently have dimensions ranging from 500 to 1,000 nm.
  • the particles generally have more than five lamellae and their concentric rings are slowly degrading; they gradually release their contents which is diffused externally as the concentration in the outer phase decreases.
  • the high number of lamellae allows a better re- tention of the hydrosoluble molecules with respect to other types of vesicles .
  • the liposomes used in the preparation/composition, object of the invention are of the pro-liposome type, i.e. liposomes which are formed during the processing phases of the preparation.
  • Phospholipids are conveniently supplied in the form of disorderly amassed bilayers and the formation of the liposomes is triggered by the addition, under stirring, of a suitable quantity of excess water with respect to the mixture of active principles.
  • the composition of the invention also comprises a biopolymer obtained from sweet almond proteins . This biopolymer consists of a three-dimensional network of high-molecular- weight proteins (higher than 500,000 daltons) which is adsorbed at the skin surface forming a continuous elastic film with an immediate lifting effect.
  • This network is obtained through the formation of crossed bonds - with the help of a polymerizing agent - between monomers having dimensions, structure and solubility perfectly de- fined, selected and controlled by the enzymatic hydrolysis of sweet almond proteins .
  • the main production steps for obtaining said biopolymer are the following:
  • the visco-elastic film which is formed on the skin as a result of this peptide network represents a soft and comfortable support which reinforces the lifting effects described above.
  • the composition of the invention also comprises a malt extract rich in pep- tides, typically having the following amino acid composition: hydroxyproline 0.6%, asparagine 10.48%, threonine 3.02%, serine 4.55%, glutamine 20.11%, proline 8.92%, glycine 9.56%, alanine 7.50%, valine 6.57%, methionine 1.39%, isoleucine 4.12%, leucine 7.71%, tyrosine 1.81%, phenylalanine 4.05%, histidine 2.06%, hydroxylysine 0.26%, lysine 3.34%, arginine 3.94%.
  • a malt extract rich in pep- tides typically having the following amino acid composition: hydroxyproline 0.6%, asparagine 10.48%, threonine 3.02%, serine 4.55%, glutamine 20.11%, proline 8.92%, glycine 9.56%, alanine 7.50%, valine 6.57%, methion
  • biopeptides preferably obtained by means of bacterial transformation techniques, acquire specific biological activities making them capable of acting as a cell messenger on the cells synthesizing the laminins, stimulating them to produce said glycoproteins.
  • the increase in the presence of laminins which decreases with age, contributes to increasing the resistance and tonic- ity of the epidermis.
  • in vitro tests were carried out on reconstituted mature skin; it was observed that the presence of the active principle in the culture medium causes a 61% increase in the production of laminins with respect to a placebo, after 14 days of incubation.
  • the malt extract is preferably carried in cyclodextrin to obtain a delayed release of the active principles contained therein.
  • Cyclodextrins are natural cyclic oligosaccharides made up of 6, 7 or 8 monomers of D- (+) glucopyranose joined to each other with an ⁇ ,l-4 glucoside bond and ring closed.
  • cyclodextrins are capable of hosting substances of a lipophilic nature in their cavity, forming inclusion complexes of the su- pramolecular type.
  • the formation of an inclusion complex with cyclodextrins causes an improvement in the physico- chemical properties of the included substance and causes a considerable increase in its solubility in water.
  • the compositions of the invention are adopted for topical use by application on the skin of the face and/or body subject to skin sagging.
  • compositions of the invention can be produced in any of the typical forms suitable for local application such as oils, aqueous solutions, hydro-alcoholic solutions, gels, lipogels, ointments, emulsions, pastes, sticks, patches.
  • composition of the invention is valid for a cosmetic lifting intervention, but the use of an applicator-doser which measures the right quantity of the preparation suitable for treating the various parts of the face and body, is preferably appropriate .
  • compositions of the invention are prepared by adding the active principles and dispersing them inside a physiologically acceptable carrier according to procedures known to experts in the field, conveniently adding one or more additive substances such as stabilizers, emulsifying agents, excipients, preservatives and sus- pending agents.
  • compositions of the invention are conveniently suitable for local application and can comprise additives and excipients commonly used in cosmetic preparations, such as preservatives, bactericidal agents, sta- bilizers, emulsifying agents, buffers, dyes, perfumes and other excipients .
  • Formulation a) Glyceryl stearate 2-6%
  • Vitamin E and/or 0.05-3% Vitamin C 0.01-2%
  • Tripeptide of Lysine-valine-lysine 0.001-5%
  • Vitamin E and/or 0.05-3% Vitamin C 0.01-2%
  • Tripeptide of Lysine-valine-lysine 0.001-5%
  • Vitamin E and/or 0.05-3% Vitamin C 0.01-2%
  • EXAMPLE 3 Formulations b) of the compositions according to Ex- amples 1 and 2 were used as bases for effecting an efficacy study in the form of a household use test, having an overall duration of 30 days on a group of 80 female volunteers, aged between 30 and 60 years old with skin re- laxation localized on the face, breast, stomach and glutei. They applied 4 cosmetic compositions defined as day cream, breast cream, stomach cream and gluteus cream.
  • formulation b) of example 1 was used as a base for breast, stomach and gluteus products
  • formulation b) of example 2 was used as a base for the day cream
  • the body creams used typically contained vegetable extracts differing in the application areas and specifically Equisetum extract for the breast, Echinacea extract for the stomach and Centella extract for the glutei.
  • the subjects selected for the study used the products being tested applying them on the skin areas under examination, for 30 consecutive days, as follows: in the morning the day cream for the face and the breast cream, in the evening the stomach and gluteus cream.
  • Face attachment product once a day (evening), taking 1 ml of product with a graded doser and dividing it between face and neck, gently massaging for at least 1 minute /
  • a household use test was carried out with laboratory controls, having an overall duration of 30 days, during which the volunteers used the products being tested applying them on the skin of the stomach, as follows : - Stomach attachment product: once a day (evening), taking 3 ml of product with a graded doser and gently massaging for at least 1 minute;

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur une composition cosmétique dont l'effet liftant soutient les tissus cutanés relâchés et réduit leur affaissement. Cette composition comprend de l'algue Aosa (Ulva Lactuca) ou un extrait de l'algue, associé à au moins un polypeptide choisi parmi l'arginine-glycine-acide aspartique et la lysine-valine-lysine, dans un support cosmétiquement acceptable.
PCT/IB2008/001237 2007-05-29 2008-05-07 Composition cosmétique à effet liftant pour soutenir les tissus cutanés relâchés WO2008146116A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08750974A EP2148651A2 (fr) 2007-05-29 2008-05-07 Composition cosmétique à effet liftant pour soutenir les tissus cutanés relâchés

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH00851/07 2007-05-29
CH00851/07A CH696838A5 (it) 2007-05-29 2007-05-29 Composizione cosmetica ad effetto lifting per sostenere tessuti cutanei rilassati.

Publications (2)

Publication Number Publication Date
WO2008146116A2 true WO2008146116A2 (fr) 2008-12-04
WO2008146116A3 WO2008146116A3 (fr) 2009-01-29

Family

ID=38824921

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/001237 WO2008146116A2 (fr) 2007-05-29 2008-05-07 Composition cosmétique à effet liftant pour soutenir les tissus cutanés relâchés

Country Status (3)

Country Link
EP (1) EP2148651A2 (fr)
CH (1) CH696838A5 (fr)
WO (1) WO2008146116A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093388A3 (fr) * 2011-01-03 2012-11-01 Nidaria Technology Ltd. Compositions d'écran solaire biologique
WO2013150253A1 (fr) 2012-04-06 2013-10-10 Greentech Nouveaux composés oligosaccharides et leur utilisation cosmétique
ITUB20152059A1 (it) * 2015-07-10 2017-01-10 Enrico Giotti S P A Composto intorbidante e aromatizzante per bevande contenente ulvani
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
CN116035923A (zh) * 2022-11-19 2023-05-02 陕西未来生物基质工程有限公司 一种含神经酰胺&rgd多肽的纳米乳液及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02178207A (ja) * 1988-12-28 1990-07-11 Kanebo Ltd 皮膚化粧料
ATE350389T1 (de) * 2003-05-08 2007-01-15 Pentapharm Ag Tripeptide und deren derivate für die kosmetische verwendung zur verbesserung der hautstruktur
CH693818A5 (it) * 2003-07-21 2004-02-27 Gecomwert Anstalt Preparato per uso topico con efficacia elasticizzante e modellante sui tessuti cutanei.
US7025966B2 (en) * 2003-12-05 2006-04-11 Mary Kay Inc. Compositions of marine botanicals to provide nutrition to aging and environmentally damaged skin

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093388A3 (fr) * 2011-01-03 2012-11-01 Nidaria Technology Ltd. Compositions d'écran solaire biologique
WO2013150253A1 (fr) 2012-04-06 2013-10-10 Greentech Nouveaux composés oligosaccharides et leur utilisation cosmétique
JP2015515524A (ja) * 2012-04-06 2015-05-28 グリーンテック 新規なオリゴ糖化合物及びその化粧品としての使用方法
ITUB20152059A1 (it) * 2015-07-10 2017-01-10 Enrico Giotti S P A Composto intorbidante e aromatizzante per bevande contenente ulvani
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11633451B2 (en) 2016-03-31 2023-04-25 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US11998575B2 (en) 2016-03-31 2024-06-04 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
CN116035923A (zh) * 2022-11-19 2023-05-02 陕西未来生物基质工程有限公司 一种含神经酰胺&rgd多肽的纳米乳液及其制备方法和应用

Also Published As

Publication number Publication date
EP2148651A2 (fr) 2010-02-03
CH696838A5 (it) 2007-12-31
WO2008146116A3 (fr) 2009-01-29

Similar Documents

Publication Publication Date Title
JP5789278B2 (ja) 皮膚の保湿性、肌理、及び外観を改善するための、植物を主成分とする調合物
KR102265730B1 (ko) 피부 주름 개선 및 미백용 화장료 조성물
EP1555999B1 (fr) Utilisation cosmétique du kombucha pour lutter contre le vieillissement de la peau
US6620419B1 (en) Cosmetic or dermopharmaceutical use of peptides for healing, hydrating and improving skin appearance during natural or induced ageing (heliodermia, pollution)
KR101912478B1 (ko) 피부, 점막, 모발 및/또는 손발톱의 치료 및/또는 관리를 위한 엑소폴리사카라이드
JPH10509735A (ja) ビタミンｃ若しくはその誘導体又はそれらの類似体の、皮膚エラスチン合成促進のための使用
JP2001522791A (ja) 表皮細胞の機能性向上のためのｄ−キシロース、そのエステル類及びキシロース含有オリゴ糖類の使用。
US11285093B2 (en) Cosmetic uses of swertiamarin
EP2148651A2 (fr) Composition cosmétique à effet liftant pour soutenir les tissus cutanés relâchés
CN109152727B (zh) 可可豆的肽和糖水解产物、含有其的化妆品组合物以及该化妆品组合物的化妆品用途
KR102139472B1 (ko) 기능성 펩타이드와 발효물을 포함하는 피부노화 개선용 조성물
CN111686068A (zh) 一种抗皱活肤霜及其制备方法
KR102630938B1 (ko) 피부 투과성 및 성분 안정성을 개선한 피부 재생과 피부 보습 및 주름 개선용 화장료 조성물 및 그의 제조 방법
CN105705154A (zh) 北美金缕梅提取物的化妆品学和/或皮肤病学用途
JP2023547984A (ja) 組織由来マトリキン組成物及びその方法
US20070116789A1 (en) Extracts of durian fruit for use in skin care compositions
WO2008080443A2 (fr) Composition cosmétique pour le traitement et/ou la prévention des vergetures
KR102432887B1 (ko) 피부용 화장품 및 식용 필름을 포함하는 피부건강 개선용 세트 및 이를 이용한 피부미용방법
CN116747151A (zh) 一种抗衰组合物及其制备方法与应用
JP2006219432A (ja) 肌荒れ防止作用を有する組成物および化粧料、飲料
CN109350576A (zh) 具有补水保湿功效的组合物及其应用、化妆水及其制备方法
CN115040448A (zh) 一种强化抗老效果的护肤品及其制备方法
KR101997231B1 (ko) 효소반응을 이용하여 제조된 꿀 추출물을 유효성분으로 함유하는 화장료 조성물
US20130338078A1 (en) Skin care formulations including octapeptide complexes and methods for their manufacture
US20160220477A1 (en) Cosmetic or dermatological use of an extract of tapirira guianensis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08750974

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008750974

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载